Outcome
| Type |
Measure |
Description |
Time frame |
Safety issue |
| Primary |
Number of Participants With At Least One Treatment Emergent Adverse Event (TEAE) |
An adverse event (AE) is defined as any untoward medical occurrence in a clinical trial participant and that does not necessarily have a causal relationship with the treatment. A TEAE is defined as an AE that occurred after the administration of investigational medicinal product (IMP). |
From the first dose of study drug up to the end of the Post-treatment Follow-up Period (Up to Day 365) |
|
| Primary |
Number of Participants With Abnormal Physical Examination Values |
Physical examination included the examination of the abdomen; extremities; head, eyes, ears, nose (HEENT); neurological; skin and mucosae; thorax; urogenital; audiometry assessment and visual assessment. Participants with abnormal values, as assessed by the investigator were reported. |
From the first dose of study drug up to the end of the Post-treatment Follow-up Period (Up to Day 365) |
|
| Primary |
Number of Participants With Clinically Significant Abnormal Vital Sign Values |
Vital signs included weight (kg), height (cm), body temperature (degree Celsius), heart rate (beats/min), respiratory rate (breaths/minute), systolic and diastolic blood pressure (mm Hg), body mass index (BMI) (kg/m^2). The criteria for clinically significant abnormal value for weight was decrease or increase of >=5% in body weight relative to Baseline. Only categories with data for potentially clinically significant abnormal vital sign parameter values are reported. |
From the first dose of study drug up to the end of the Post-treatment Follow-up Period (Up to Day 365) |
|
| Primary |
Number of Participants With Clinically Significant Abnormalities in Electrocardiogram (ECG) Values |
The criteria for clinically significant abnormal ECG values were ventricular rate outlier (<50 bpm and decrease of >=25%, >100 bpm and increase of >=25%), PR outlier (increase of >=25% when PR >200 milliseconds (ms)), QRS outlier (increase of >=25% when QRS >100 ms), QT (new onset (in treatment period but not at Baseline) [>500 ms]), QT interval corrected by Bazett's formula (QTcB) (new onset [>450, >480, >500 ms], increase of >=30 ms and <= 60 ms or increase of >60 ms), QT interval corrected by Fridericia's formula (QTcF) (new onset [>450, >480, >500 ms], increase of >=30 ms and <= 60 ms or increase of >60 ms), new abnormal U waves, new ST segment changes, new T wave changes, new abnormal rhythm, new conduction abnormality were reported as categories. Only categories with data are reported. |
From the first dose of study drug up to the end of the Post-treatment Follow-up Period (Up to Day 365) |
|
| Primary |
Number of Participants With Clinically Significant Laboratory Test Abnormalities |
Laboratory assessments included parameters for serum chemistry, hematology and urinalysis along with adrenocorticotropic hormone, serum cortisol, free thyroxine, thyroid-stimulating hormone (TSH), and high sensitivity C-reactive protein cell count. The participants were categorized based on the clinically significant laboratory values as per protocol predefined criteria. The categories with at least one participant with clinically significant value outside the normal range for laboratory assessments are reported. The normal ranges for those laboratory parameters were potassium 3.4 - 5.4 milliequivalents/liter (mEq/L), uric acid 3.9 - 8.2 mg/dL, partial thromboplastin time (PTT) 9.7 - 12.3 sec, platelet count 180 - 440 thousands platelets/µL. |
From the first dose of study drug up to the end of the Post-treatment Follow-up Period (Up to Day 365) |
|
| Primary |
Population Pharmacokinetic (POPPK) Model Point Estimate for Central Clearance (L) and Inter-compartmental Clearance (Q) of Delamanid |
Central clearance is defined as plasma volume in the vascular compartment that is cleared of drug per unit of time. Inter-compartmental clearance is defined as a ratio of the drug's distribution rate between the central compartment and the peripheral compartments over its circulating concentration (L/hr). Population point estimates were based on POPPK analysis to find one measure each for both L and Q. The exposure data were pooled across visits and participants to identify POPPK parameter estimates and were reported for delamanid. |
Predose on Days 1, 56, 154, and 182, 210 and at any time point on Days 14, 98, 189, 196, 203, and 238 |
|
| Primary |
POPPK Model Point Estimate for Central Volume of Distribution (Vc) and Peripheral Volume of Distribution (Vp) of Delamanid |
Vc is defined as the theoretical volume that would be necessary to contain the total amount of an administered drug at the same concentration that it is observed in the blood plasma. Vp is defined as the apparent volume needed to account for the total amount of drug in the body if the drug was evenly distributed throughout the body and in the same concentration as the site of sample collection such as peripheral venous plasma. Population point estimates were based on POPPK analysis to find one measure each for both Vc and Vp. The exposure data were pooled across visits and participants to identify POPPK parameter estimates and were reported for delamanid. |
Predose on Days 1, 56, 154, and 182, 210 and at any time point on Days 14, 98, 189, 196, 203, and 238 |
|
| Primary |
POPPK Model Point Estimate for Absorption Rate Constant (Ka) of Delamanid |
Ka is defined as a measure of rate at which a drug enters into the circulatory system. Population point estimate for Ka was based on population PK analysis to find one measure. Population point estimates were based on POPPK analysis to find one measure for Ka. The exposure data were pooled across visits and participants to identify POPPK parameter estimates and were reported for delamanid. |
Predose on Days 1, 56, 154, and 182, 210 and at any time point on Days 14, 98, 189, 196, 203, and 238 |
|
| Primary |
POPPK Model Point Estimate for Absorption Lag Time (ALAG1) of Delamanid |
ALAG1 is defined as the time delay prior to the commencement of drug absorption. Population point estimates were based on POPPK analysis to find one measure for ALAG1. The exposure data were pooled across visits and participants to identify POPPK parameter estimates and were reported for delamanid. |
Predose on Days 1, 56, 154, and 182, 210 and at any time point on Days 14, 98, 189, 196, 203, and 238 |
|
| Secondary |
Baseline QT Interval (QTcB) Effect |
The 12-lead ECG was performed to obtain recordings of heart rate (QT interval) to analyze QTcB effect. |
Baseline (Day -1) |
|
| Secondary |
PK/PD Relationship: POPPK Model Point Estimate for Slope of Linear Mixed Effects Model for Change in QTcB Interval Versus Delamanid Plasma Concentrations |
The linear mixed effects model was applied to characterize the concentration-QTcB relationship of delamanid/DM-6705 to obtain population slope estimate. |
Predose on Days 1, 56, 154, and 182, 210 and at any time point on Days 14, 98, 189, 196, 203, and 238 |
|
| Secondary |
Number of Participants With Treatment Outcome as Assessed by Principal Investigator |
Treatment outcome was defined as favorable (cured and completed treatment) and unfavorable (lost to follow-up or died). |
Month 24 |
|
| Secondary |
Number of Participants With Abnormal Chest X-ray |
The data for the chest X-ray with abnormality, as assessed by investigator is reported. |
From the first dose of study drug up to the end of the Post-treatment Follow-up Period (Up to Day 365) |
|
| Secondary |
Number of Participants With Investigator-Assessed Signs and Symptoms of Tuberculosis |
The following signs and symptoms of tuberculosis were assessed by the investigator: cough, fever, weight loss, failure to thrive, hemoptysis, dyspnea, chest pain, night sweats and loss of appetite. |
From the first dose of study drug up to the end of the Post-treatment Follow-up Period (Up to Day 365) |
|
| Secondary |
Sputum Culture Conversion (SCC) |
SCC was defined as a sputum specimen from a participant negative for growth of Mycobacterium tuberculosis (MTB), followed by at least one confirmatory negative sputum culture at least 27 days after the first negative sputum test and not followed by any sputum cultures positive for growth. |
From the first dose of study drug up to the end of the Post-treatment Follow-up Period (Up to Day 365) |
|
| Secondary |
Number of Participants With Palatability Score as Assessed by the Investigator |
The palatability of the pediatric formulation was assessed using an age-appropriate visual hedonic scale and clinical assessment (Groups 3 and 4 only). The palatability result was based on 1 of 5 responses: 1=Dislike very much, 2=Dislike a little, 3=Neither liked nor disliked, 4=Like a little, 5=Like very much. Participants were categorized based on different scores. The data per the investigator score are reported. |
Days 1, 28, 56 and 182 |
|
| Secondary |
Number of Participants With Palatability Score as Assessed by the Parent or Participant |
The palatability of the pediatric formulation was assessed using an age-appropriate visual hedonic scale and clinical assessment (Groups 3 and 4 only). The palatability result was based on 1 of 5 responses: 1=Dislike very much, 2=Dislike a little, 3=Neither liked nor disliked, 4=Like a little, 5=Like very much. The data per parent/patient score are reported. Participants were categorized based on different scores. |
Days 1, 28, 56 and 182 |
|
